Proprotein convertase subtilisin/kexin type 9 (PCSK9) has gained considerable attention over the past decade due to its role in elevating plasma levels of low density lipoprotein cholesterol (LDL–C), a major causal risk factor of coronary artery disease (CAD), by promoting the degradation of LDL receptors (LDL-R) in the liver1,2. The gene discussed is LDLR; the disease is coronary artery disorder.